Date: 2014-06-23
Type of information: Collaboration agreement
Compound: novel small molecule remyelinating therapies
Company: Roche (Switzerland) Inception Sciences (USA - CA) Versant Venture (USA - PA)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Type agreement: collaboration
Action mechanism:
Disease: multiple sclerosis
Details: * On June 23, 2014, Roche announced that it has entered into an exclusive partnership with the drug discovery incubator Inception Sciences, and Versant Ventures to create Inception 5, a new company dedicated to the research and development of novel small molecule remyelinating therapies for patients with multiple sclerosis. The collaboration will focus on screening and developing novel small molecule therapies that aim to promote remyelination of nerve sheaths damaged as a result of multiple sclerosis disease progression. Inception 5 will build on recent discoveries in the field and a proprietary remyelination screening platform developed by investigators at the University of California, San Francisco. The company will pursue multiple molecular targets for remyelination that have already been identified. Versant will provide equity financing to the company and Roche will fund the research based on a series of milestones. Roche retains an exclusive option to acquire Inception 5 upon a first lead compound reaching the filing stage of an investigational new drug (IND) application
Financial terms:
Latest news:
